Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 1:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Edematous Skin Clear all
Recruiting Phase 2 Interventional Accepts healthy volunteers

Tranexamic Acid in Nasal Mohs Reconstruction

NCT06057675
View directory record Official record
Conditions
Postoperative Bleeding, Skin Cancer Face
Interventions
Treatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine), Control (1% lidocaine with 1:100,000 epinephrine)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 22, 2026, 1:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Open-label, Non Significant Risk, Adhesive Wear Validation Study for the On Body Drug Delivery Device Component of the SQIN-01 Furosemide Infusor (Infusor Device)

NCT04836572
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
3M 1529 Adhesive Tape
Other
Lead sponsor
SQ Innovation, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Marlborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Sep 22, 2026, 1:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP

NCT03675685
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy
Interventions
CCH (collagenase clostridium histolyticum)
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Sep 22, 2026, 1:51 PM EDT
Completed No phase listed Observational Results available

Safety and Feasibility of Prima-Temp Thermometer Patch

NCT01587014
View directory record Official record
Conditions
Erythema, Edema, Papules White, Eruption
Interventions
Not listed
Lead sponsor
Poudre Valley Health System
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Loveland, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 19, 2017 · Synced Sep 22, 2026, 1:51 PM EDT
Completed Phase 2 Interventional Results available

Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks

NCT05419505
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
CCH-aaes, Antifibrinolytic Agent
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
13
States / cities
Scottsdale, Arizona • Beverly Hills, California • Encinitas, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 22, 2026, 1:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A 12 Week Study to Evaluate the Efficacy of an Eye Cream

NCT05807620
View directory record Official record
Conditions
Periorbital Hyperpigmentation, Periorbital Edema, Fine Lines, Wrinkle
Interventions
Gentle Cleansing Lotion, Facial Moisturizer, Sunscreen SPF 30
Other
Lead sponsor
Revision Skincare
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 22, 2026, 1:51 PM EDT
Terminated Phase 1 Interventional

Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema

NCT00517582
View directory record Official record
Conditions
Angioneurotic Edema
Interventions
HOE-140, Placebo
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Sep 22, 2026, 1:51 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women

NCT04209530
View directory record Official record
Conditions
Cellulite, Edematous Fibrosclerotic Panniculopathy (EFP)
Interventions
EN3835
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 22, 2026, 1:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite

NCT04677712
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy (EFP), Cellulite
Interventions
CCH-aaes, Compression, Cold Packs, Arnica Gel, INhance®, PDL
Drug · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
8
States / cities
Scottsdale, Arizona • Sacramento, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 22, 2026, 1:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Single-Center, Clinical Study to Evaluate the Safety of a Non-Fragranced Personal Lubricant in Healthy Female Subjects

NCT02320227
View directory record Official record
Conditions
Erythema, Edema
Interventions
Miami w/o frag Personal lubricant
Device
Lead sponsor
Church & Dwight Company, Inc.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 22, 2026, 1:51 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery

NCT04951128
View directory record Official record
Conditions
Edema, Ecchymosis; Eyelid
Interventions
Tranexamic acid injection, Local anesthetic control
Drug · Other
Lead sponsor
Consultants in Ophthalmic and Facial Plastics Surgery
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
4
States / cities
Southfield, Michigan • The Bronx, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Sep 22, 2026, 1:51 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effects of Hyperbaric Oxygen Therapy on Surgical Wound Healing

NCT01605110
View directory record Official record
Conditions
Edema, Ecchymosis
Interventions
Hyperbaric oxygen treatment, Air sham
Drug
Lead sponsor
Restorix Research Institute, LLLP
Other
Eligibility
40 Years to 85 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Issaquah, Washington
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Sep 22, 2026, 1:51 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)

NCT05836779
View directory record Official record
Conditions
Cellulite
Interventions
CBL-514 injection
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Encinitas, California • Encino, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 22, 2026, 1:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Human Repeat Insult Patch Test to Evaluate Personal Lubricants

NCT02737631
View directory record Official record
Conditions
Erythema, Edema
Interventions
"Chameleon" Personal Lubricant
Device
Lead sponsor
Church & Dwight Company, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
222 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Sep 22, 2026, 1:51 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)

NCT03632993
View directory record Official record
Conditions
Edematous Skin
Interventions
collagenase clostridium histolyticum (CCH)
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
5
States / cities
Coral Gables, Florida • Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 22, 2026, 1:51 PM EDT
Active, not recruiting Phase 2 Interventional

Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer

NCT02912312
View directory record Official record
Conditions
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
12
States / cities
Gilbert, Arizona • San Diego, California • Greeley, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 22, 2026, 1:51 PM EDT
Completed Phase 2 Interventional Results available

Micro-mobile Foot Compression and Diabetic Foot

NCT03135535
View directory record Official record
Conditions
Diabetes, PAD, Lower Extremity Edema, Neuropathy;Peripheral, Foot Ulcer, Diabetic, Lymphatic Diseases
Interventions
Avex Footbeat
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 22, 2026, 1:51 PM EDT
Withdrawn Not applicable Interventional

The Mount Sinai Diabetic Foot Ulcer Prospective Trial

NCT03404895
View directory record Official record
Conditions
Diabetes, Diabetic Foot Ulcer, Edema
Interventions
Conventional Therapy, Venous Stent(s)
Device
Lead sponsor
Windsor Ting
Other
Eligibility
30 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 22, 2026, 1:51 PM EDT
Recruiting Phase 3 Interventional

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

NCT06361537
View directory record Official record
Conditions
Acute Hereditary Angio Edema
Interventions
OCTA-C1-INH, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
2 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Centennial, Colorado • Farmington Hills, Michigan • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 22, 2026, 1:51 PM EDT
Terminated Phase 2 Interventional Results available

DDAVP in the Reduction of Post-operative Ecchymosis in Rhinoplasty

NCT01982760
View directory record Official record
Conditions
Postoperative Ecchymosis
Interventions
DDAVP
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Lyndhurst, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Sep 22, 2026, 1:51 PM EDT
Completed No phase listed Observational

Durability and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women

NCT03893890
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy
Interventions
Previously Treated with EN3835
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
5
States / cities
Clearwater, Florida • Coral Gables, Florida • Washington, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Sep 22, 2026, 1:51 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques

NCT04580303
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite, Laxity; Skin
Interventions
collagenase clostridium histolyticum
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Coral Gables, Florida • Metairie, Louisiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 22, 2026, 1:51 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)

NCT05632926
View directory record Official record
Conditions
Cellulite
Interventions
40 mg CBL-514, 60 mg CBL-514, 80 mg CBL-514
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
Encino, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 22, 2026, 1:51 PM EDT
Completed No phase listed Observational

Long-term Durability Study of Collagenase Clostridium Histolyticum (CCH)

NCT04381117
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy
Interventions
Previously Treated with EN3835
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Clearwater, Florida • Coral Gables, Florida • Washington, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 22, 2026, 1:51 PM EDT